Clinical trials: Psilocybin, completed
Amnestic Mild Cognitive Impairment
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
The goal of this pilot, exploratory, clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants…
- Trial name
- NCT06041152
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Psychedelic Experiences
Safety for Home Administration of Microdose Psilocybin Use
The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants.
- Trial name
- NCT06450210
- Testing
- psilocybin trihydrate
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy Volunteers
Psilocybin Brain Stimulation and Imaging Pilot Study
This open-label pilot psilocybin administration study investigates the influence of psilocybin on brain function and cognitive control functions in clinically and psychiatrically healthy volunteers.
- Trial name
- OPTE (NCT06835699)
- Testing
- Psilocybin 25 mgs, TMS
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy Controls
Identification of a Safe and Non-Psychedelic Dose of Psilocybin
This randomized, double-blind, placebo-controlled, single ascending dose study will evaluate psilocybin in healthy adult subjects.
- Trial name
- NCT07710027
- Where
- Canada
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Diamond Therapeutics Inc.
Healthy
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
The acute subjective effects of serotonin (5-HT)2A receptor stimulation with psilocybin in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking, or loss of trust towards other people are common…
- Trial name
- MDMA-Psilo (NCT06884514)
- Testing
- Psilocybin, 3,4-Methylenedioxymethamphetamine
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy Volunteer
A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple…
- Trial name
- NCT07050368
- Testing
- Psilocybin
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- MycoMedica Life Sciences PBC
Healthy
Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans
The study looks into whether administering psychedelic substances that stimulate the serotonin system influences pro-social behavior when compared to administering substances that stimulate the dopamine system in healthy…
- Trial name
- NCT06081179
- Testing
- Psilocybin, 3,4 Methylenedioxymethamphetamine, Methylphenidate
- Where
- Switzerland
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Psilocybin
Precision Functional Brain Mapping in Psilocybin
This project will employ functional brain imaging to study the mechanism and immediate and long-term effects of psilocybin, a serotonin receptor 2A agonist, on cortical and cortico-subcortical brain networks in healthy adults.
- Trial name
- Psilocybin PFM (NCT04501653)
- Testing
- Psilocybin, Methylphenidate
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Autism Spectrum Disorder
Psilocybin in Adults With and Without Autism Spectrum Disorder
This study will test the hypothesis that brain systems are differentially regulated by serotonin in individuals with and without Autism Spectrum Disorder.
- Trial name
- PSILAUT (NCT05651126)
- Testing
- Psilocybin 5 mg, Psilocybin 2 mg
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- King's College London
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is…
- Trial name
- NCT06643637
- Testing
- Psilocybin
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- MycoMedica Life Sciences PBC
Nicotine Dependence
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
One of the most promising lines of investigation for the therapeutic use of hallucinogens in the 1960s and 1970s was in the treatment of drug dependence.
- Trial name
- NCT01943994
- Testing
- Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT)
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy, Psychedelic Experiences
Consciousness, Psilocybin, and Well-Being
This study is being done to identify a dosing strategy that will allow IV psilocybin to be administered to sleeping participants without awakening them.
- Conditions
- Healthy, Psychedelic Experiences, Sleep
- Trial name
- CoPE Pilot (NCT05592379)
- Testing
- Psilocybin, Clonidine, Saline
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Depressive Disorder, Treatment-Resistant
Psilocybin-assisted Interpersonal Therapy for Depression
This is a single-arm, open-label interventional study of psilocybin-assisted interpersonal therapy for treatment resistant depression.
- Trial name
- NCT05581797
- Testing
- Psilocybin-assisted psychotherapy
- Where
- New Zealand
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Otago
Healthy
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects
4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic…
- Trial name
- 2C-B (NCT05523401)
- Testing
- 4-bromo-2,5-dimethoxyphenethylamine (10 mg), 4-bromo-2,5-dimethoxyphenethylamine (20 mg), 4-bromo-2,5-dimethoxyphenethylamine (30 mg)
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants
MLS101 is being developed as a low dose psilocybin, that can be administered to treat various neurological and psychiatric conditions.
- Trial name
- NCT06326606
- Testing
- Psilocybin
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- MycoMedica Life Sciences PBC
Healthy
Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion
The current protocol is a pilot study of the effects and possible utility of psilocybin-facilitated experiences for professional religious leaders.
- Trial name
- NCT02243813
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy
Comparative Acute Effects of LSD, Psilocybin and Mescaline
LSD, psilocybin and mescaline are widely used for recreational and ethnomedical purposes. All three substances are thought to induce prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor.
- Trial name
- LPM (NCT04227756)
- Testing
- LSD, Psilocybin, Mescaline
- Where
- Switzerland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
QTc Interval, Pharmacokinetics
An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics
This study is comprised of two parts. The purpose of the first part of this study is to evaluate the effects of a supratherapeutic dose of psilocybin on cardiac repolarization.
- Trial name
- NCT05478278
- Testing
- Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Usona Institute
Psychedelic Experiences, Amnesia
Pilot RECAP Study in Healthy Volunteers
The primary objective of the RECAP Study Program is to investigate the role played by conscious experience in the antidepressant effects of the psychedelic agent psilocybin.
- Trial name
- RECAP (NCT04842045)
- Testing
- Psilocybin and Midazolam
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Religious or Spiritual Problem
The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals
The current protocol is a pilot study of the effects and possible utility of psilocybin-facilitated experiences for professional religious leaders.
- Trial name
- NCT02421263
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health